Cris Loiren Rodriguez

Array ( [id] => 13552591 [patent_doc_number] => 20180327843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => USE OF IL-3, IL-33, AND IL-12p40 FOR CHARACTERIZATION OF THE RESPIRATORY INFECTIONS BY SYNCYTIAL RESPIRATORY VIRUS [patent_app_type] => utility [patent_app_number] => 15/748984 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401742 [patent_doc_number] => 20170022280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHOD FOR TREATING ANTIBODY-MEDIATED REJECTION POST-TRANSPLANTATION' [patent_app_type] => utility [patent_app_number] => 15/219121 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 14762 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15219121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12037661 [patent_doc_number] => 09815880 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-14 [patent_title] => 'IL-22 Fc fusion proteins' [patent_app_type] => utility [patent_app_number] => 15/217790 [patent_app_country] => US [patent_app_date] => 2016-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 175 [patent_no_of_words] => 58090 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15217790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114924 [patent_doc_number] => 20160311897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F' [patent_app_type] => utility [patent_app_number] => 15/208202 [patent_app_country] => US [patent_app_date] => 2016-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 39909 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15208202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13647979 [patent_doc_number] => 09850294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-26 [patent_title] => IL-17R-ECD mutants and methods of using same [patent_app_type] => utility [patent_app_number] => 15/205074 [patent_app_country] => US [patent_app_date] => 2016-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 14059 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15205074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300273 [patent_doc_number] => 20180201673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => TREATMENT OF PRURITUS [patent_app_type] => utility [patent_app_number] => 15/742542 [patent_app_country] => US [patent_app_date] => 2016-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15742542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11291811 [patent_doc_number] => 20160341744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/198262 [patent_app_country] => US [patent_app_date] => 2016-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17794 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15198262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083816 [patent_doc_number] => 20160280781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'IL-17 ANTIBODY FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/178583 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6986 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15178583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053365 [patent_doc_number] => 20160250326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'Conjugates of GM-CSF and IL-7, and Compositions Thereof' [patent_app_type] => utility [patent_app_number] => 15/157647 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 24842 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15157647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350217 [patent_doc_number] => 20160368957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'IL-17 Binding Compounds and Medical Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/156983 [patent_app_country] => US [patent_app_date] => 2016-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 15804 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15156983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13331243 [patent_doc_number] => 20180217159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => BIOMARKERS FOR PREDICTING A RESPONSE TO AN IMMUNOMODULATING TREATMENT IN PATIENTS WITH INFLAMMATORY DISEASE [patent_app_type] => utility [patent_app_number] => 15/572279 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16335612 [patent_doc_number] => 10786550 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease [patent_app_type] => utility [patent_app_number] => 15/148102 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 33 [patent_no_of_words] => 37426 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584940 [patent_doc_number] => 20180086809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => A SOLUBLE CHIMERIC INTERLEUKIN-10 RECEPTOR AND THERAPEUTIC USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/562557 [patent_app_country] => US [patent_app_date] => 2016-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067698 [patent_doc_number] => 20160264661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'ANTI-IL-12/IL-23 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/136355 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 59125 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15136355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054466 [patent_doc_number] => 20160251429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'NEUTRALISING ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17' [patent_app_type] => utility [patent_app_number] => 15/056956 [patent_app_country] => US [patent_app_date] => 2016-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13806 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15056956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11048851 [patent_doc_number] => 20160245809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'Ligand Conjugated Quantum Dots for the Detection of Soluble Receptors and Exosomes in Biological Fluids' [patent_app_type] => utility [patent_app_number] => 15/048180 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11950 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15048180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440801 [patent_doc_number] => 20180271943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => METHODS FOR TREATING INFLAMMATION WITH TGF-BETA [patent_app_type] => utility [patent_app_number] => 15/544940 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702671 [patent_doc_number] => 20170362290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => IL-17A-BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 15/538890 [patent_app_country] => US [patent_app_date] => 2016-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15538890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717225 [patent_doc_number] => 20170369567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/538266 [patent_app_country] => US [patent_app_date] => 2015-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15538266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16680756 [patent_doc_number] => 10940212 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => IL-21 agonist antibodies and methods of treatment using same [patent_app_type] => utility [patent_app_number] => 15/537095 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 27007 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 395 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15537095 [rel_patent_id] =>[rel_patent_doc_number] =>)